Neurocrine Biosciences Stock News

Neurocrine Biosciences, Inc. (NBIX) shares closed today at 0.3% above its 52 week low of $84.50, giving the company a market cap of $8B. The stock is currently down 9.3% year-to-date, down 9.0% over the past 12 months, and up 76.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 41.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -220.1% The company's stock price performance over the past 12 months lags the peer average by -152.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -14.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

DNB Asset Management AS reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 14.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,279 shares of the companys stock after selling 19,944 shares during the quarter. DNB Asset Management AS []

Neurocrine Biosciences (NASDAQ:NBIX) and Sutro Biopharma (NASDAQ:STRO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Volatility and Risk Neurocrine Biosciences has a beta of 0.7, indicating that its stock price is […]

State of Alaska Department of Revenue trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,526 shares of the companys stock after selling 157 shares during the quarter. State of []

San Diego-based company plans to develop medications for neurological disorders Related Stocks: NBIX , SOLTF , LLY , PFE , MRK , BMY , AZN , GSK , AMGN , SNY , FRA:SNY , STU:SNY ,

Following disappointing third-quarter earnings, Neurocrine Biosciences, Inc. ( NBIX , Financial) shareholders were looking for a shred of good news that could boost the price of the San-Diego-based bi

Eight months after Neurocrine $NBIX chronicled a flop for a mid-stage schizophrenia drug, the biotech is headed right back into Phase II armed with a new drug candidate from Sosei Heptares. Neurocrine outlined a deal that provides Sosei Heptares $100 million upfront, R&D expenses and a motherlode of milestones worth

Thrivent Financial for Lutherans raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,099 shares of the companys stock after buying an additional 124 shares during the quarter. Thrivent Financial for Lutherans []

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been given a consensus rating of Hold by the twenty brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and nine have given a buy recommendation to the company. The average []

BMO Capital Markets began coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report issued on Thursday, Price Targets.com reports. The brokerage issued an underperform rating and a $76.00 price objective on the stock. Other research analysts also recently issued research reports about the company. Citigroup lowered their target price on Neurocrine Biosciences from $132.00 []

Louisiana State Employees Retirement System reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,100 shares of the companys stock after selling 400 shares during the period. Louisiana State Employees Retirement Systems []

JPMorgan Chase & Co. upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a neutral rating to an overweight rating in a report released on Wednesday morning, Price Targets.com reports. They currently have $124.00 price objective on the stock. A number of other research firms also recently issued reports on NBIX. Royal Bank of Canada lowered their []

Comerica Bank raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 26.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 144,730 shares of the companys stock after purchasing an additional 29,856 shares during the quarter. Comerica Bank owned 0.15% of Neurocrine Biosciences worth $12,959,000 []

Sharp down days are when to look for surprise values in underpriced stocks. Not the story issues being ballyhooed by touts and the media - everyone knows them. The hidden values are ones found by expe